logo.gif
Auris Medical Provides Update on Intranasal Betahistine Development Program
April 03, 2020 17:00 ET | Auris Medical AG
Phase 1b trial with AM-201 proceeding as planned to data read-out in early May 2020Enrollment into Phase 2 trial with AM-125 impacted by COVID-19 pandemicCompany to report 2019 second-half and full...
logo.gif
Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine
March 05, 2020 08:30 ET | Auris Medical AG
Last subject had last treatment visit in Phase 1b trial with AM-201 in prevention of antipsychotic-induced weight gain and somnolence; data read-out expected for early May 2020Phase 2 trial with...
logo.gif
Auris Medical Highlights Publication of Study Results Demonstrating Betahistine’s Antiepileptogenic and Anticonvulsant Activity in Murine Model
February 25, 2020 08:30 ET | Auris Medical AG
Hamilton, Bermuda, February 25, 2020 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
logo.gif
Auris Medical Announces Notice of Allowance for European Patent Application
January 10, 2020 08:30 ET | Auris Medical AG
Received “Intention to Grant” notice from European Patent OfficeApplication covers invention of oral treatment for tinnitus Hamilton, Bermuda, January 10, 2020 – Auris Medical Holding Ltd. (NASDAQ:...
logo.gif
Auris Medical Announces Formation of New Subsidiary for Development Projects in Tinnitus and Hearing Loss
December 30, 2019 08:30 ET | Auris Medical AG
Hamilton, Bermuda, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
logo.gif
Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain
October 11, 2019 08:30 ET | Auris Medical AG
Hamilton, Bermuda, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
logo.gif
Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program
September 13, 2019 09:00 ET | Auris Medical AG
Hamilton, Bermuda, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
logo.gif
Auris Medical Announces Notices of Allowance for U.S. and European Patent Applications Covering Intranasal Betahistine
September 11, 2019 09:00 ET | Auris Medical AG
Hamilton, Bermuda, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
logo.gif
Auris Medical Announces Appointment of New Chief Financial Officer
September 04, 2019 07:00 ET | Auris Medical AG
Hamilton, Bermuda, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
logo.gif
Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs
August 26, 2019 09:00 ET | Auris Medical AG
Hamilton, Bermuda, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...